Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)
  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information.
 
DevicePRESTIGE® Cervical Disc
Generic NameProsthesis, intervertebral disc
ApplicantMEDTRONIC SOFAMOR DANEK, INC.
1800 Pyramid Place
Memphis, TN 38132
PMA NumberP060018
Supplement NumberS004
Date Received01/29/2016
Decision Date07/20/2016
Withdrawal Date 03/25/2021
Product Code MJO 
Advisory Committee Orthopedic
Clinical TrialsNCT00642876
Supplement TypeNormal 180 Day Track No User Fee
Supplement Reason Labeling Change - PAS
Expedited Review Granted? No
Combination ProductNo
Approval Order Statement  
Approval for 1) A 7-year post-approval study to evaluate the longer term safety and effectiveness of the PRESTIGE Cervical Disc. The study will involve the investigational and control patients from the pivotal investigational device exemption (IDE) study arm, as well as the patients who received the device as part of the continued access study (CAS) arm. Data will be collected at 3 years (36 months), 5 years (60 months), and 7 years (84 months) postoperatively for all patients. At each time point, Medtronic will collect the following data: Neck Disability Index score; radiographic information; and neurological status. In addition, all adverse events, including details of the nature, onset, duration, severity, relationship to the device, and relationship to the operative procedure and outcome reported for these patients will also be collected. Reports will be submitted annually until the completion of the study. The results of this long-term data must be reflected in the labeling (via supplement) when the post-approval study is completed, as well as any other time point deemed necessary by FDA if significant new information from this study becomes available.2) A 5-year enhanced surveillance study of the PRESTIGE Cervical Disc to fully characterize adverse events when the device is used in a broader patient population. Medtronic will collect, analyze, and submit all adverse events and complaints received by the company for the PRESTIGE Cervical Disc, as well as information on the total number of devices shipped. The study will commence at the time of PMA approval and reports will be submitted every six months for the first two years and then annually through the fifth year.
-
-